MDRX Veradigm
- 7.720
- -0.070-0.90%
Veradigm News
8 Out of 12 S&P 500 Healthcare Companies Beat Profit Consensus This Week: Earnings Scorecard
MedEvolve Announces Strategic Marketing Relationship With Veradigm to Enhance Revenue Cycle Management Solutions for Healthcare Organizations
LITTLE ROCK, Ark.--(BUSINESS WIRE)--MedEvolve, a leading provider of effective intelligence technology that provides, automation, transparency and accountability for the healthcare revenue cycle, is p
Veradigm Network Solution Practice Fusion EHR Receives Top Ambulatory Rankings
CHICAGO--(BUSINESS WIRE)--#healthIT--Veradigm(OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book, a healthcare-centric market research and
Veradigm and Vim to Improve Payer-Provider Collaboration
Poised to revolutionize point-of-care integration for payers, creating a more seamless and efficient healthcare experience for providers and patients alikeCHICAGO--(BUSINESS WIRE)--#healthIT--Veradigm
Deutsche Bank Downgrades Veradigm to Hold From Buy, Adjusts Price Target to $10 From $15
Deutsche Bank Downgrades Veradigm to Hold From Buy, Adjusts Price Target to $10 From $15.
TrustCommerce Cloud Payments Platform Now Integrated With Practice Fusion, A Veradigm Network Solution
Seamless integration enables providers using Practice Fusion EHR to securely accept and post payments within existing workflows MELVILLE, N.Y., March 19, 2024 /PRNewswire/ -- TrustCommerce, a Sphere
Allscripts Cut to Hold From Buy by Deutsche Bank
Allscripts Cut to Hold From Buy by Deutsche Bank
Deutsche Bank Downgrades Veradigm to Hold, Lowers Price Target to $10
Deutsche Bank analyst George Hill downgrades Veradigm from Buy to Hold and lowers the price target from $15 to $10.
Veradigm Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/19/2024 19.76% Deutsche Bank $15 → $10 Downgrades Buy → Hold 01/19/2024 31.74% RBC Capital $22 → $11 Ma
Veradigm's Challenging Outlook: Hold Rating Justified Amid Revenue Growth, Margin Pressures, and Audit Concerns
Analysts Conflicted on These Healthcare Names: Veradigm (OtherMDRX), ADC Therapeutics (ADCT) and Sangamo Biosciences (SGMO)
(SEC Amendment) Veradigm(MDRX.US) 10% Shareholder Buys US$66 Million in Common Stocks
$Veradigm(MDRX.US)$ 10% Shareholder STONEHILL CAPITAL MANAGEMENT LLC purchased 10.22 million shares of Common Stocks on Feb 28, 29, Mar 1, 2024 at an average price of $6.46 for a total value of $66 mi
Veradigm to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
CHICAGO--(BUSINESS WIRE)--#healthIT--Veradigm Inc. (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions announced today that Dr. Yin Ho, Veradigm Interim Chief Executive Off
Veradigm Reports Initial Financial Outlook for Fiscal 2024
Veradigm Highlights Strategies at Barclays Healthcare Conference
Veradigm(MDRX.US) 10% Shareholder Buys US$66 Million in Common Stocks
$Veradigm(MDRX.US)$ 10% Shareholder STONEHILL CAPITAL MANAGEMENT LLC purchased 10.22 million shares of Common Stocks on Feb 28, 29, Mar 1, 2024 at an average price of $6.46 for a total value of $66 mi
Veradigm to Participate in Barclays 26th Annual Global Healthcare Conference
CHICAGO--(BUSINESS WIRE)--#healthIT--Veradigm Inc. (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions announced today that Dr. Yin Ho, Veradigm interim Chief Executive Off
Veradigm Completes Acquisition of ScienceIO
CHICAGO--(BUSINESS WIRE)--#healthIT--Veradigm Inc. (OTCMKTS: MDRX) (the "Company"), a leading provider of healthcare data and technology products and solutions, today announced that it has completed i
Sprinklr Set to Join S&P SmallCap 600
Sprinklr To Replace Veradigm In S&P SmallCap 600 Effective Prior To Opening Of Trading On March 4, 2024
Veradigm will be suspended from the Nasdaq Stock Market on February 29 due to non-compliance with NASDAQ listing rules and is no longer eligible for continued inclusion in the S&P SmallCap 600.
Analysis
Price Target
No Data
